

Day 2 May 21 (Thu.) 2026

Plenary Session

Scientific Program

Educational Session

Free Papers(Oral)

Social Event

English Session

Simultaneous Interpretation

Live Streaming Session

		7:00	8:00	9:00	10:00	11:00	12:00	13:00	14:00	15:00	16:00	17:00	18:00	19:00	20:00	21:00	
PACIFICO Yokohama Conference Center	Room 1 Main Hall (1F)		Web Symposium 12 ICAD and RNF213-Related Vasculopathy in East Asia			Web PL-01 Plenary Lecture 01 Speaker: Josep Dalmau Chair: Takahiro Iizuka	LS-15 Eisai Japan / Biogen Japan	Web Pr President Lecture Speaker: Kazutoshi Nishiyama Chair: Fumihiko Sakai	Web JSN Awards Ceremony	Web 2026 Special Symposium 01 Envisioning the Future of the Japanese Society of Neurology							
	Room 2 301 (3F)		Symposium 13 ALS and lipid metabolism abnormalities: pathophysiological analysis for treatment strategies and iPS cell drug discovery		O-10 Motor neuron disease 2		LS-16 Novartis Pharma K.K.		Japanese Society of Neurology 2025 Award Winner Lecture		Hot Topics 05 Cell Transplantation Therapy for Parkinson's Disease: Clinical Trajectory and Future Outlook				ES-01 Eli Lilly Japan K.K. / Daiichi Sankyo Co., Ltd.		
	Room 3 302 (3F)		Web Symposium 14 The cutting edge strategies for management of breakthrough stroke		O-11 Cerebrovascular disease 2		LS-17 UCB Japan Co., Ltd.				Web Symposium 20 Principles and Practice of Preventive Neurology: a rapidly burgeoning field of Neurology						
	Room 4 303 (3F)		Symposium 15 Migraine pathophysiology: An in-depth analysis		O-12 Parkinson's disease 2		LS-18 AbbVie GK				Symposium 21 Neurology meets Pharmacogenomics(PGx)						
	Room 5 304 (3F)				O-13 Clinical neurophysiology		LS-19 Alexion Pharma GK										
	Room 6 311+312 (3F)				O-14 Neuroradiology, Functional image		LS-20 GlaxoSmithKline K.K.								ES-02 CHUGAI PHARMACEUTICAL CO., LTD.		
	Room 7 313+314 (3F)						LS-21 Medical Affairs, Lundbeck Japan K.K.								ES-03 ONO PHARMACEUTICAL CO., LTD.		
	Room 8 315 (3F)		Symposium 16 State-of-the-Art Insights into the Pathogenesis of Repeat-Associated Muscle Diseases		O-15 Dystonia/ Involuntary movement		LS-22 CHUGAI PHARMACEUTICAL CO., LTD.				Hot Topics 06 Clinical Neurorehabilitation: A quarter century of progress and future outlook				ES-04 Novartis Pharma K.K.		
	Room 9 414+415 (4F)		Hot Topics 04 Frontiers in the Treatment of Spinocerebellar Degeneration — From Rehabilitation to Clinical Trials		O-16 Cerebellar ataxia · Spastic paraplegia 2		LS-23 SCRUM Inc				Hot Topics 07 The Future of Gene Editing in Neurological Disease Therapy: From CRISPR to Japan-Originated Technologies at the Forefront of Research				ES-05 PDRadiopharma Inc. / The Japanese Council of Nuclear Neuroimaging / Japanese Society of Nuclear Medicine		
	Room 10 416+417 (4F)		Web Symposium 17 Do neurologic diseases start at the autonomic nerves?		O-17 Parkinson's syndrome		LS-24 FP Pharmaceutical Corporation				Web Symposium 22 How to access and treat gait disorders				ES-06 Japan Blood Products Organization		
	Room 11 418 (4F)		Symposium 18 Advances in Inherited Peripheral Neuropathies: Latest Findings in Molecular, Clinical, and Pathological Research		O-18 Neurogenetics		LS-25 Novo Nordisk Pharma Ltd.				Symposium 23 Exploring the pathomechanism of neurological diseases from the perspective of endoplasmic reticulum function -From basic science to human neuropathology -						
	Room 12 419 (4F)		Meet the Expert Meet the AAN President: Emerging Leadership in Neurology -Perspectives from Young and Female Physicians-		O-19 Neuroinfection		LS-26 Alnylam Japan K.K.				LB Late Breaking Symposium						
	Room 13 501 (5F)		LM-03 Lecture Marathon 03	LM-04 Lecture Marathon 04	O-20 Neuroimmunology 2 (MS · NMO)		LS-27 Eli Lilly Japan K.K.				LM-05 Lecture Marathon 05	LM-06 Lecture Marathon 06			ES-07 Eisai Co., Ltd.		
	Room 14 502 (5F)		New Guideline 02 Clinical practice guidelines for HTLV-1-associated myelopathy 2025		O-21 Dementia and related pathologies		LS-28 argenx Japan K.K.				Symposium 24 Advances in Imaging Biomarkers in Multiple Sclerosis				ES-08 Medical Affairs Division, Johnson & Johnson		
	Room 15 503 (5F)		Symposium 19 Understanding pathogenesis for therapeutic strategy of MG in the future		O-22 Neuromuscular junction disease		LS-29 Tanabe Pharma Corporation				Symposium 25 Considering the co-pathogenesis in neurodegenerative diseases						
Poster Session	Hall B (1F)	Poster Preparation / Poster Viewing					Poster Viewing					Poster Presentation / Discussion					Poster Removal
Exhibition		Exhibition															

DAY 2